ARCHIVES

Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

Zometa Reduced Bone Complications In Patients With Prostate Cancer Bone Mets

October 25, 2002

FDA Ceases Exclusion Of Women From Early Drug Studies

May 7, 1993

Collaborative Drug Development Groups Clear BSC Overview, Natural Products RFA To Proceed

June 10, 1988

NCI Cooperative Group, Cancer Center Trials Listed

October 31, 2008

Field Studies Chief Leave For Job with Upton; Sibal Named DCCP Acting Deputy

October 27, 1978

In Brief: Walter Lawrence, Reginald Ho Lead ACS; Henderson To Leave Dana-Farber for UCSF

November 22, 1991